Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy

Omar Alshuwaykh, Tami Daugherty, Amanda Cheung, Aparna Goel, Renumathy Dhanasekaran, T. Tara Ghaziani, Aijaz Ahmed, Deepti Dronamraju, Radhika Kumari, Allison Kwong, Mindie Nguyen, W. Ray Kim, Paul Yien Kwo – 24 August 2022 – Chronic hepatitis B virus (HBV) infection is the leading risk factor for hepatocellular carcinoma (HCC). The aim of this study was to explore the incidence of HCC in a cohort of subjects with HBV and correlate with HBV treatment current guidance. We identified 2846 subjects with HBV over the study period.

β‐catenin cancer–enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma

Ruhi Gulati, Michael Johnston, Maria Rivas, Ashley Cast, Meenasri Kumbaji, Margaret A. Hanlon, Sanghoon Lee, Ping Zhou, Charissa Lake, Emily Schepers, Kyung‐Won Min, Je‐Hyun Yoon, Rebekah Karns, Lola M. Reid, Dolores Lopez‐Terrada, Lubov Timchenko, Sreeja Parameswaran, Matthew T. Weirauch, Sarangarajan Ranganathan, Alexander Bondoc, James Geller, Gregory Tiao, Soona Shin, Nikolai Timchenko – 23 August 2022 – Fibrolamellar hepatocellular carcinoma (FLC) is a disease that occurs in children and young adults.

The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti‐mitochondrial antibodies but without baseline PBC

Weijia Duan, Sha Chen, Shuxiang Li, Tingting Lv, Buer Li, Xiaoming Wang, Yu Wang, Xinyan Zhao, Hong Ma, Xiaojuan Ou, Hong You, Jidong Jia – 22 August 2022 – Anti‐mitochondrial autoantibodies (AMAs) are highly specific for the diagnosis of primary biliary cholangitis (PBC) but are also occasionally found in other diseases. In the present study, we evaluated the incidence of and predictors for PBC development in AMA‐positive patients with other liver or non‐liver diseases at baseline.

Granulocyte colony‐stimulating factor attenuates liver damage by M2 macrophage polarization and hepatocyte proliferation in alcoholic hepatitis in mice

Yeonhee Cho, Radhika Joshi, Patrick Lowe, Christopher Copeland, Marcelle Ribeiro, Caroline Morel, Donna Catalano, Gyongyi Szabo – 22 August 2022 – Massive inflammation and liver failure are main contributors to the high mortality in alcohol‐associated hepatitis (AH). In recent clinical trials, granulocyte colony‐stimulating factor (G‐CSF) therapy improved liver function and survival in patients with AH. However, the mechanisms of G‐CSF‐mediated beneficial effects in AH remain elusive. In this study, we evaluated effects of in vivo G‐CSF administration, using a mouse model of AH.

Health disparities in chronic liver disease

Ani Kardashian, Marina Serper, Norah Terrault, Lauren D. Nephew – 21 August 2022 – The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations. Highlighting health disparities, their sources, and consequences in chronic liver disease is fundamental to improving liver health outcomes.

Subscribe to